<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> is a new oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi> used to treat transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Pre-marketing clinical trials revealed little organ-specific toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Increases in serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> were noted in one-third of patients but were mild and non-progressive </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a 62-year-old man with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> who developed a progressive decline in renal function after starting <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>A kidney biopsy showed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001970'>interstitial nephritis</z:hpo> with increased eosinophils, suggesting <z:e sem="disease" ids="C0013182" disease_type="Disease or Syndrome" abbrv="">drug hypersensitivity</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> was discontinued and renal function returned to baseline </plain></SENT>
<SENT sid="6" pm="."><plain>This is the first pathological description of <z:chebi fb="0" ids="49005">deferasirox</z:chebi>-related <z:hpo ids='HP_0001919'>acute kidney injury</z:hpo> in humans, which differs from tubular vacuolization observed in animals </plain></SENT>
</text></document>